Actively Recruiting

Phase 2
Age: 5Years - 17Years
All Genders
NCT07287982

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

Led by argenx · Updated on 2026-04-22

60

Participants Needed

17

Research Sites

179 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study aims to find the correct dose of ARGX-119 for children with SMA. The study will also look at how safe the study drug is, how well it works, how it moves through the body, and how the immune system responds to it. The study consists of a double-blinded treatment period (DBTP) where participants will either receive ARGX-119 IV or placebo IV, in addition to disease-modifying therapy (DMT) for 24 weeks. Participants who complete the DBTP will enter the open-label active-treatment extension period (ATEP) during which all participants will receive ARGX-119 IV up to 100 weeks (approximately 2 years).

CONDITIONS

Official Title

A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

Who Can Participate

Age: 5Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Is aged ≥5 to <18 years when completing the informed consent process, defined as providing informed assent according to local regulations and having a parent or guardian sign the ICF, and can comply with protocol
  • requirements.
  • Has documented historical genetic diagnosis of 5q-SMA.
  • Currently receiving a stable SMA treatment regimen (nusinersen or risdiplam) and/or have a history of onasemnogene abeparvovec treatment
  • Must be able to walk at least 50 meters without walking aids in the 6MWT at screening
Not Eligible

You will not qualify if you...

  • Known medical condition that would interfere with an accurate assessment of SMA, confound the results of the study, or put the participant at undue risk, as assessed by the investigator
  • Recent major surgery, except spinal fusion, within 3 months of screening or intends to have major surgery during the study
  • Current or previous administration of antimyostatin therapies in the past 6 months
  • Severe scoliosis (defined as curvature >40°) and/or contractures at screening. o History of spinal fusion within 6 months before screening or planned during the study
  • Respiratory insufficiency, defined by the medical necessity for invasive or noninvasive ventilation for daytime treatment while awake. Ventilation used overnight or during daytime naps is acceptable.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 17 locations

1

Arkansas Children's Hospital

Little Rock, Arkansas, United States, 72202

Actively Recruiting

2

Rady Childrens Hospital

San Diego, California, United States, 92123

Not Yet Recruiting

3

Stanford University Medical Center

Stanford, California, United States, 94305

Not Yet Recruiting

4

Connecticut Children's Medical Center

Hartford, Connecticut, United States, 06106

Not Yet Recruiting

5

Rare Disease Research FL LLC

Kissimmee, Florida, United States, 34746

Actively Recruiting

6

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States, 60611

Not Yet Recruiting

7

University of Iowa Stead Family Children's Hospital

Iowa City, Iowa, United States, 52242

Not Yet Recruiting

8

The Johns Hopkins Hospital

Baltimore, Maryland, United States, 21205

Not Yet Recruiting

9

Boston Children's Hospital

Boston, Massachusetts, United States, 02115

Not Yet Recruiting

10

The Curators of the University of Missouri on behalf of University of Missouri Health Care

Columbia, Missouri, United States, 65212

Not Yet Recruiting

11

Columbia University Herbert Irving Comprehensive Cancer Center

New York, New York, United States, 10032

Not Yet Recruiting

12

Rare Disease Research NC, LLC

Hillsborough, North Carolina, United States, 27278

Actively Recruiting

13

Children's Hospital Philadelphia - Neurology

Philadelphia, Pennsylvania, United States, 19104

Not Yet Recruiting

14

St. Jude Children's Research Hospital

Memphis, Tennessee, United States, 38105

Not Yet Recruiting

15

Neurology Rare Disease Center

Flower Mound, Texas, United States, 75028

Actively Recruiting

16

Texas Children's Hospital

Houston, Texas, United States, 77030

Not Yet Recruiting

17

Childrens Hospital of The Kings Daughters

Norfolk, Virginia, United States, 23507

Not Yet Recruiting

Loading map...

Research Team

S

Sabine Coppieters, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here